Fosaprepitant Dimeglumine for the Management of Chemotherapy-induced Nausea and Vomiting: Patient Selection and Perspectives

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2016 Jul 7

PMID 27382332

Citations 5

Authors

Nellowe Candelario

Marvin Louis Roy Lu

Affiliations

Soon will be listed here.

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of antineoplastic agents. Several treatment regimens are used to address this problem. Fosaprepitant is a neurokinin-1 receptor blocker used in the prevention and treatment of CINV, especially for moderately and severely emetogenic chemotherapy. It is highly effective in the treatment of delayed CINV. Data from previous studies show that fosaprepitant is noninferior to aprepitant in the management of CINV. Fosaprepitant is given as a single-dose intravenous infusion, thus offering better patient compliance. The dose-limiting side effect of fosaprepitant is an infusion-related reaction, ranging from pain at the infusion site to thrombophlebitis. This side effect has been reported with coadministration of anthracycline agents.

Citing Articles

Comparing Injection Site Reactions of Aprepitant and Fosaprepitant in Gynecologic Cancer Chemotherapy.

Nishibe-Toyosato S, Ando Y, Torii Y, Ichikawa R, Owaki A, Miyamura H In Vivo. 2024; 38(5):2374-2382.

PMID: 39187311 PMC: 11363802. DOI: 10.21873/invivo.13704.

Comparative Study Between Fosaprepitant and Palonosetron in the Prophylaxis of Postoperative Nausea and Vomiting in Women Undergoing Laparoscopic Cholecystectomy: Prospective, Randomized and Double-Blind Study.

Braga E, Vercosa N, Cavalcanti I Front Pharmacol. 2022; 13:915347.

PMID: 35645797 PMC: 9130472. DOI: 10.3389/fphar.2022.915347.

A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC.

Matsuura K, Tsurutani J, Inoue K, Tanabe Y, Taira T, Kubota K Cancer. 2022; 128(8):1692-1698.

PMID: 35045185 PMC: 9306508. DOI: 10.1002/cncr.34088.

Structural insights of human N-acetyltransferase 10 and identification of its potential novel inhibitors.

Dalhat M, Altayb H, Imran Khan M, Choudhry H Sci Rep. 2021; 11(1):6051.

PMID: 33723305 PMC: 7960695. DOI: 10.1038/s41598-021-84908-0.

Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD44.

Wang T, Hou J, Su C, Zhao L, Shi Y J Nanobiotechnology. 2017; 15(1):7.

PMID: 28068992 PMC: 5223569. DOI: 10.1186/s12951-016-0245-2.

References

Celio L, Ricchini F, De Braud F . Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. Patient Prefer Adherence. 2013; 7:391-400. PMC: 3653760. DOI: 10.2147/PPA.S31288. View

Janelsins M, Tejani M, Kamen C, Peoples A, Mustian K, Morrow G . Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother. 2013; 14(6):757-66. PMC: 3938333. DOI: 10.1517/14656566.2013.776541. View

Lundberg J, Crawford B, Phillips G, Berger M, Wesolowski R . Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. Support Care Cancer. 2014; 22(6):1461-6. PMC: 4277851. DOI: 10.1007/s00520-013-2106-y. View

Kamen C, Tejani M, Chandwani K, Janelsins M, Peoples A, Roscoe J . Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol. 2013; 722:172-9. PMC: 3880638. DOI: 10.1016/j.ejphar.2013.09.071. View

Sato Y, Kondo M, Inagaki A, Komatsu H, Okada C, Naruse K . Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients. J Cancer. 2014; 5(5):390-7. PMC: 4007527. DOI: 10.7150/jca.7706. View

Blackshaw L, Brookes S, Grundy D, Schemann M . Sensory transmission in the gastrointestinal tract. Neurogastroenterol Motil. 2007; 19(1 Suppl):1-19. DOI: 10.1111/j.1365-2982.2006.00871.x. View

Hegerova L, Leal A, Grendahl D, Seisler D, Sorgatz K, Anderson K . An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2014; 23(1):55-9. PMC: 4383176. DOI: 10.1007/s00520-014-2326-9. View

Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L . Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1997; 15(1):116-23. DOI: 10.1200/JCO.1997.15.1.116. View

Dushenkov A, Kalabalik J, Carbone A, Jungsuwadee P . Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice. J Oncol Pharm Pract. 2016; 23(4):296-308. DOI: 10.1177/1078155216631408. View

10.

Colon-Gonzalez F, Kraft W . Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol. 2010; 6(10):1277-86. PMC: 3155701. DOI: 10.1517/17425255.2010.513970. View

11.

Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M . Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol. 2012; 24(4):1067-73. PMC: 3603438. DOI: 10.1093/annonc/mds541. View

12.

Schnell F . Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003; 8(2):187-98. DOI: 10.1634/theoncologist.8-2-187. View

13.

Cohen L, de Moor C, Eisenberg P, Ming E, Hu H . Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2006; 15(5):497-503. DOI: 10.1007/s00520-006-0173-z. View

14.

Basch E, Prestrud A, Hesketh P, Kris M, Feyer P, Somerfield M . Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011; 29(31):4189-98. PMC: 4876353. DOI: 10.1200/JCO.2010.34.4614. View

15.

Micha J, Rettenmaier M, Brown 3rd J, Mendivil A, Abaid L, Lopez K . A Randomized Controlled Pilot Study Comparing the Impact of Aprepitant and Fosaprepitant on Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecologic Cancer. Int J Gynecol Cancer. 2015; 26(2):389-93. DOI: 10.1097/IGC.0000000000000593. View

16.

Weinstein C, Jordan K, Green S, Camacho E, Khanani S, Beckford-Brathwaite E . Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol. 2015; 27(1):172-8. PMC: 4684151. DOI: 10.1093/annonc/mdv482. View

17.

Leal A, Kadakia K, Looker S, Hilger C, Sorgatz K, Anderson K . Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer. 2014; 22(5):1313-7. PMC: 3969765. DOI: 10.1007/s00520-013-2089-8. View

18.

Roila F, Herrstedt J, Aapro M, Gralla R, Einhorn L, Ballatori E . Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010; 21 Suppl 5:v232-43. DOI: 10.1093/annonc/mdq194. View

19.

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice J . Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011; 29(11):1495-501. DOI: 10.1200/JCO.2010.31.7859. View

20.

Grundy D . 5-HT system in the gut: roles in the regulation of visceral sensitivity and motor functions. Eur Rev Med Pharmacol Sci. 2008; 12 Suppl 1:63-7. View